PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
Achievement of initial efficacy milestone allows full enrollment of checkpoint inhibitor naïve cohort FLORHAM PARK,…